Key Points Viking is testing weight loss drug candidates in late-stage trials. The company recently showed that weight loss lasts after taking its drug candidate. 10 stocks we like better than Viking Therapeutics › Today, a very valuable market -- one heading toward $100 billion by the end of the decade -- is dominated by two pharma giants, Eli Lilly and Novo Nordisk . And this is the weight loss drug market. Lilly and Novo each sell GLP-1 drugs, products that have seen soaring demand and have delivered blockbuster revenue. But a new potential player is waiting in the wings and has been taking important steps forward.
Wir zeigen den wichtigsten Punkt oeffentlich. Erstellen Sie ein kostenloses Konto, um den vollstaendigen Artikel zu lesen, ihn zu speichern, zu diskutieren und mit Markt- und OSINT-Kontext zu verbinden.